Let’s dig into the relative performance of Neogen (NASDAQ:NEOG) and its peers as we unravel the now-completed Q3 medical ...

Despite operational strength, SYK trades at a significant valuation premium to sector peers, with a PEG ratio above 2 and ...

Stryker continues to deliver strong organic growth, having posted organic growth rates of around 10% for a long period of time now. Learn more about SYK stock here.

What Happened? Shares of medical technology company Stryker (NYSE:SYK) fell 2.9% in the afternoon session after it reported ...

Stryker's Q3 results top estimates with double-digit sales and profit growth, but shares slip as investors weigh tariff pressures despite an upbeat 2025 outlook.

Analysts have recently evaluated Stryker and provided 12-month price targets. The average target is $417.57, accompanied by a ...

Stryker Corp (SYK) reports robust sales and EPS growth, raises full-year outlook despite facing tariff and supply chain ...

Stryker (NYSE:SYK) shares dipped slightly today on third-quarter results that topped the consensus Wall Street forecast.

Stryker on Thursday raised the lower end of its full-year profit forecast after beating estimates for third-quarter earnings, banking on strong demand for its medical and surgical devices.

Medical technology company Stryker (NYSE:SYK) met Wall Streets revenue expectations in Q3 CY2025, with sales up 10.2% year on year to $6.06 billion. Its non-GAAP profit of $3.19 per share was 1.9% ...

Portage, Michigan, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the third quarter of 2025: Reported net sales increased 10.3% to $6.1 billion Organic net sales ...

The medical products maker now expects sales to grow 9.8% to 10.2% in the full year.